Clinical pharmacology of flurbiprofen: a novel inhibitor of platelet aggregation.
Studies are reviewed of the inhibitory effect of flurbiprofen, given in doses ranging from 50 mg to 200 mg per day for 1 week, on platelet aggregation measured by biological tests (adenosine diphosphate and collagen methods). Flurbiprofen at doses of 50 mg and 100 mg daily had a peak time of action of between 1 and 2 hours, the effects usually disappearing after 24 hours, and 100 mg flurbiprofen caused a similar decrease in platelet aggregation to 1 g aspirin daily. In a clinical study of 72 patients with chronic glomerulonephritis treated with doses of flurbiprofen up to 200 daily there was a significant correlation between the parameters of aggregation measured and treatment, and between proteinuria and adenosine disphosphate aggregation when the flurbiprofen dose did not exceed 100 mg daily.
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors; D002908:Chronic Disease; D003094:Collagen / Q000037:antagonists & inhibitors; D004305:Dose-Response Relationship, Drug; D005480:Flurbiprofen / Q000494:pharmacology* / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000188:drug therapy; D006801:Humans; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects*; D011422:Propionates / Q000494:pharmacology*; D011507:Proteinuria / Q000188:drug therapy
D011422:Propionates; D005480:Flurbiprofen; D000244:Adenosine Diphosphate; D003094:Collagen